Lonza Group Ltd (LZAGY)
57.41
+0.77
(+1.36%)
USD |
OTCM |
May 03, 16:00
Lonza Group Enterprise Value: 42.82B for May 3, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 03, 2024 | 42.82B |
| May 02, 2024 | 42.27B |
| May 01, 2024 | 41.18B |
| April 30, 2024 | 41.32B |
| April 29, 2024 | 42.72B |
| April 26, 2024 | 43.10B |
| April 25, 2024 | 42.17B |
| April 24, 2024 | 42.72B |
| April 23, 2024 | 42.94B |
| April 22, 2024 | 41.58B |
| April 19, 2024 | 41.19B |
| April 18, 2024 | 41.55B |
| April 17, 2024 | 42.74B |
| April 16, 2024 | 42.99B |
| April 15, 2024 | 43.28B |
| April 12, 2024 | 43.44B |
| April 11, 2024 | 44.36B |
| April 10, 2024 | 43.74B |
| April 09, 2024 | 45.08B |
| April 08, 2024 | 45.76B |
| April 05, 2024 | 45.12B |
| April 04, 2024 | 44.68B |
| April 03, 2024 | 44.71B |
| April 02, 2024 | 43.77B |
| April 01, 2024 | 44.73B |
| Date | Value |
|---|---|
| March 28, 2024 | 44.63B |
| March 27, 2024 | 44.28B |
| March 26, 2024 | 43.87B |
| March 25, 2024 | 43.61B |
| March 22, 2024 | 43.93B |
| March 21, 2024 | 43.30B |
| March 20, 2024 | 43.06B |
| March 19, 2024 | 40.43B |
| March 18, 2024 | 40.15B |
| March 15, 2024 | 40.05B |
| March 14, 2024 | 40.67B |
| March 13, 2024 | 40.08B |
| March 12, 2024 | 39.09B |
| March 11, 2024 | 39.13B |
| March 08, 2024 | 39.50B |
| March 07, 2024 | 39.70B |
| March 06, 2024 | 38.50B |
| March 05, 2024 | 38.49B |
| March 04, 2024 | 39.16B |
| March 01, 2024 | 39.51B |
| February 29, 2024 | 39.13B |
| February 28, 2024 | 39.37B |
| February 27, 2024 | 39.51B |
| February 26, 2024 | 39.14B |
| February 23, 2024 | 39.34B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
26.19B
Minimum
May 13 2019
66.93B
Maximum
Aug 27 2021
42.98B
Average
42.85B
Median
Mar 08 2023
Enterprise Value Benchmarks
| Roche Holding AG | 217.22B |
| AC Immune SA | 113.68M |
| CRISPR Therapeutics AG | 3.050B |
| Addex Therapeutics Ltd | 4.963M |
| NLS Pharmaceutics Ltd | -- |
Enterprise Value Related Metrics
| Earnings Yield | 1.73% |
| Operating Earnings Yield | 2.31% |
| Normalized Earnings Yield | 1.737 |